The cellular function of kinases combined with the difficulty of designing selective small molecule kinase inhibitors (SMKIs) poses a challenge for drug development. The late-stage attrition of SMKIs could be lessened by integrating safety information of kinases into the lead optimization stage of drug development. Herein, a mathematical model to predict bone marrow toxicity (BMT) is presented which enables the rational design of SMKIs away from this safety liability. A specific example highlights how this model identifies critical structural modifications to avoid BMT. The model was built using a novel algorithm, which selects 19 representative kinases from a panel of 277 based upon their ATP-binding pocket sequences and ability to predict BMT in vivo for 48 SMKIs. A support vector machine classifier was trained on the selected kinases and accurately predicts BMT with 74% accuracy. The model provides an efficient method for understanding SMKI-induced in vivo BMT earlier in drug discovery.
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The mechanistic role kinases play in various diseases makes kinase inhibitors one of the largest classes of small molecule drugs with over 150 different kinases being considered as putative drug targets (Vieth et al., 2005) . Over the last decade, nearly a dozen small molecule kinase inhibitors (SMKIs) were marketed for various oncology indications, and a large number are in development for non-oncology indications (Kremer et al., 2009; Skvara et al., 2008) . Despite the attractiveness of kinases as drug targets, there are several inherent challenges in the development of SMKIs. Kinases have critical and often pleiotropic cellular functions, including mitosis, apoptosis, and cell signaling of the immune system, and their inhibition can lead to cytotoxicity or altered cellular differentiation, such as in hematopoiesis (Huang et al., 2009; Geest and Coffer, 2009 ). Additionally, most SMKIs competitively interact with the ATPbinding pocket of the targeted kinase to inhibit phosphorylation of the intrinsic substrate. The high degree of sequence and structural homology among protein kinases, particularly in the conserved ATP-binding pocket, makes it challenging to develop selective SMKIs, yet selectivity is critical to minimizing undesirable side effects (Busse et al., 2001) .
Bone marrow toxicity (BMT) is a common and potentially severe toxicity of SMKIs (Cortes et al., 2008; Druker et al., 2006; Gupta et al., 2009; Motzer et al., 2006; Nakagawa et al., 2003; Santos et al., 2009 ) that can hamper drug development. A number of kinases, including Flt3, Jak2, and KIT, are associated with a hematopoietic function and when inhibited correlate with hematopoietic or BMT (Agosti et al., 2009; Santos et al., 2009; Weisel et al., 2009) . Preclinically, BMT of drug candidates is assessed traditionally in a repeat dose in vivo toxicology study with hematological end points and bone marrow microscopic evaluation; however, in vitro methods are also available and have been used successfully for ranking compounds prior to commencing in vivo testing (Olaharski et al., 2009b) . Although effective, there can be a significant lag between the time when the compound is developed and assessed in these tests. Importantly, these approaches do not provide insight as to which kinases could cause the toxicity and what structural modifications to the SMKI could mitigate the toxicity.
A kinase screen is routinely used during the lead optimization phase to assess SMKI selectivity across a broad spectrum of the kinome. In this early discovery phase, medicinal chemists can leverage knowledge of kinase biology to improve characteristics of lead compounds, particularly with respect to selectivity.
Although not yet standard practice, this is an opportune time to incorporate knowledge of potential toxicity concerns of inhibiting specific kinases. To bridge this gap between in vivo toxicity screening in the preclinical phase and kinase profiling during the earlier discovery phase, a mathematical tool could be developed to incorporate kinase ATP-binding pocket sequence information, kinase inhibition, and a toxicological end point. Medicinal chemists could then use such a tool to design molecules devoid of such toxicological liabilities. The advantages of such an approach are that compounds are screened earlier, costs are reduced, timelines are shortened, and the number of animals required for preclinical toxicology studies is reduced.
The objective of this study was to develop an in silico model that predicts BMT and to provide medicinal chemists with a tool for optimizing compound design. This model identified a set of kinases that correlated with BMT and had dissimilar ATP-binding pocket sequences, thus providing medicinal chemists with tangible hypotheses to avoid kinases that correlate with BMT. Specifically, when an SMKI causes BMT, this method can highlight sequence differences between the targeted and nontargeted BMT-associated kinases and guide potential synthetic modifications to improve selectivity. These findings provide a set of ''kinases of concern'' to be avoided during lead optimization in the early discovery phase to avoid BMT during later stages of development. A novel feature selection algorithm and support vector machine (SVM) classifier were used to identify such a set of kinases and develop a fast efficient model to predict BMT in vivo. In addition to its novel utility in drug discovery, the model enhances our understanding of the biological mechanisms underlying BMT and enables the generation of hypotheses for structural modifications during lead optimization.
MATERIALS AND METHODS
Compounds. The 48 compounds were synthesized at Hoffman La-Roche or purchased from Sigma (St Louis, MO). A representative sampling of Roche's SMKI library was selected to include inhibition of a diverse set of kinases and broad chemical structures to increase robustness of the derived model. Structural diversity was assessed with Principal Component Analysis (Supplementary fig. S3 ), where each compound was represented with Extended Connectivity Fingerprints (ECFP4) in Pipeline Pilot 7.5 (Accelrys, San Diego, CA).
Kinase inhibition. All compounds were screened against a panel of 317 kinases using KINOMEscan assays (Ambit Biosciences, San Diego, CA) (Fabian et al., 2005) . For each compound-kinase pair, a high-throughput competitive-binding assay was performed. At 10lM of compound, inhibition measurements, ranging from 50 to 100%, were collected for each compoundkinase pair.
Dataset. Toxicological screening of the SMKIs for in vivo BMT was conducted at, or contracted by, Hoffmann-La Roche. These studies consisted of multiple designs with variations in dose levels, dosing duration, and species used. Studies were conducted in regulatory compliance for animal care and use. Histopathological determination of BMT occurred following pathologist peer review, whereas significant changes in peripheral blood counts (e.g., lymphocytes, neutrophils, etc.) of animals treated with the SMKI compared with vehicle controls was automatically generated using the clinical data management system ClinAccess (MAJARO InfoSystems, Inc. Santa Clara, CA). Pathology reports were reviewed by one board certified veterinary pathologist to determine drug-related affects on the bone marrow or peripheral blood. Twenty-seven of the 48 compounds were nontoxic to either and were designated ''BMT Negative'', whereas 21 compounds were toxic to either the bone marrow and/or hematopoieitic system and were designated ''BMT Positive''. After preprocessing of the Ambit data, which included exclusion of 27 mutant kinases and 13 kinases for which sequence information was not available, a 48 3 277 data matrix remained with which to generate a model for kinase inhibitor-induced BMT (Supplementary fig. S1 ).
Model methods. An algorithm was developed to identify kinases predictive of BMT with highly dissimilar binding pocket sequences. The binding pocket was defined as a superset of residue positions that represent the union of all binding pockets. Specifically, all in-house and public domain kinase-ligand crystal structures were included. The ligands were aligned, and the set of residues within 5Å of each ligand was identified. This yielded 47 residue positions for the binding pocket superset. Sequence information was obtained for 277 kinases in the Ambit panel. Subsequently, the binding pocket sequences of the 277 kinases were aligned, and a dissimilarity matrix based on the alignment scores was computed and used to create a dendrogram.
Based on the sequence alignment of the binding pocket, the kinases were clustered into k clusters using hierarchical clustering with Ward's agglomeration method in R (version 2.9.1). The number of clusters, ranging from 2 to 25, was optimized based on the silhouette criterion (Everitt et al., 2001; Kaufman and Rousseeuw, 1990) . Clusters were assessed using their average silhouette width, with a larger width representing a stronger clustering of the kinases in each cluster. Optimization yielded 19 distinct clusters. These 19 clusters represented a partition of kinase-binding pocket sequences and herein will be referred to as kinase-binding pocket sequence ''motifs.'' Fifty splits of 5-fold cross-validation were used to select features (kinases) that were predictive of BMT. Specifically, we selected the most highly correlated kinase from each of the 19 motifs based on the lowest t-statistic obtained. Within each of the 5-fold, a representative kinase from each cluster was selected, and these 19 kinases were used to train a nonlinear SVM model to predict BMT. This approach assumed that each representative kinase served as a sentinel for its binding pocket sequence motif and thus selected a highly dissimilar and nonredundant set of representative kinases. For each fold, these 19 features were used to learn a nonlinear SVM model predicting BMT. As described previously by Olaharski et al. (2009a) , a Radial Basis Function (RBF) kernel was used and the hyper-parameters of the SVM were optimized to yield a gamma of 2 À6 and cost of 1.
Selection of kinases.
To select the final model kinases, the kinases within each cluster were ranked according to the frequency by which they were selected as a cluster representative within cross-validation. These 19 kinases, one per cluster, were those most correlated with BMT within their kinasebinding pocket sequence motif. Model assessment. As described, all modeling was performed within 50 splits of 5-fold cross-validation. To assess the model, the SVM prediction of BMT labels based on the 19 representative kinases were compared with the true labels for the training set for each fold. Accuracy, sensitivity, specificity, and Area Under the Curve (AUC) were calculated for each fold. The mean performance statistics were calculated for each split and then summarized overall splits.
RESULTS

Sequence-Based Clusters
Binding site sequence data for 277 kinases in the Ambit kinase inhibition panel were obtained. Prior to clustering the kinases, the residues comprising the binding pocket of each kinase were identified and compared. Specifically, the ligands in all in-house and public domain kinase-ligand crystal structures were aligned and for each structure, the set of residues within 5Å of any ligand were considered. This yielded 47 residues, which encompass the binding pocket and additional residues. Using the aligned sequences for these 47 residues, a sequence-based dissimilarity matrix was calculated between the 277 kinases in the Ambit panel. Kinases were grouped into 19 clusters based on hierarchical clustering, using Ward's agglomeration method, of the aligned binding site sequences of the 277 kinases. A dendrogram of the kinases is shown in Figure 1 . Figure 1 is analogous to a previously published kinase dendrogram (Manning et al., 2002) ; however, it represents a more pertinent dendrogram from the drug discovery perspective of the kinome because it is specifically based on the functionally relevant ATP-binding pocket, rather than the full sequence. Supplementary table S1 lists the kinases in each cluster, along with the average silhouette width and kinase representative for each cluster.
Model kinases
Within each cluster, the kinase selected was the one most often chosen as the cluster representative based on t-statistic across the 50 splits of 5-fold cross-validation (Table 1 ). These 19 model kinases were CAMK2A, AURKC, MET, PKN1, LCK, EPHB1, TGFBR1, CDK17, PDGFRB, MYLK2, STK10, PIM2, PAK7, NEK7, DMPK, CLK1, P38a (also Note. The 19 model kinases identified by frequency of selection in final phase of model assessment. Incidence of selection and percent selected values were based on the t-statistics from intercluster t-tests within 50 splits of 5-fold cross-validation. MODELING BMT 269 known as MAPK14), CSNK1E, and MKNK2. A heat map of the percent inhibition values against these 19 kinases (Fig. 2) demonstrates a clear enrichment of kinase inhibition for SMKIs with BMT-positive results (compared with the preprocessed data set shown in Supplementary fig. S1 ).
Model performance
Final model performance was based on 50 random splits of 5-fold cross-validation. The 250 iterations yielded a crossvalidated estimate with an overall classification accuracy of 74%, sensitivity of 46%, specificity of 88%, and AUC of 78%. The receiver operating characteristic curve of the overall mean performance is shown in Figure 3 .
Assessment of kinases
A literature review of studies relating kinases to hematopoietic function (e.g., signaling, differentiation, or proliferation) identified an association in 9 of the 19 kinases such that when inhibited could theoretically lead to hematopoietic dysfunction or toxicity (Table 1) . Additionally, two other kinases had roles in mitosis (AURKC and NEK7) that could impact hematopoietic proliferation and/or differentiation, although a direct link to hematopoietic dysfunction has not been reported. Eight kinases had no reported association with hematopoietic function. Other kinases highly correlated with BMT, yet not selected in the final model because they were not as strongly correlated as their cluster representative and were not as predictive in a subset, are included in Supplementary table S2.
Application of the model
Two internal compounds, compound 1 and compound 2, were used to test the model and its application to structure based design (Fig. 4) . Compound 1 showed BMT-positive results and inhibited P38a, LCK, and PDGFRB. Compound 2 did not exhibit BMT (Supplementary fig. S2 ) and inhibited P38a, but not LCK or PDGFRB. The two compounds shared a common amino-pyrazole core. The crystal structure of another compound with the same amino-pyrazole core structure was used to develop molecular docking models in P38a and LCK (Goldstein et al., 2006) . The docking models and ligand interaction profiles for compound 1 and compound 2 were developed using methodology implemented in Molecular Operating Environment (Chemical Computing Group, Montreal, Quebec, Canada). The binding pocket sequences were examined to identify residue positions that were identical in LCK and PDGFRB, but different in P38a. Two positions were identified: P38a has a histidine and a leucine at positions 107 and 108, respectively, whereas LCK and PDGFRB have a glutamic acid and a tyrosine at these positions, respectively. This information was used to test whether the identified residues could drive the binding affinity of the compounds, thereby causing the different BMT result. The docking models explained how both compounds bind well to P38a and bind differentially to LCK. The latter was driven by the residue at position 108 in P38a, namely leucine versus tyrosine.
DISCUSSION
A statistical modeling framework was employed to identify a set of kinases predictive of BMT, as defined by bone marrow and/or peripheral hematopoietic depletion. Within this framework, a novel feature selection algorithm incorporating binding pocket sequences identified 19 kinases that correlated with this toxicological end point. A predictive model was built using an SVM classifier and the binding affinities of these 19 kinases for the selected training set of 48 SMKIs. The cross-validated prediction accuracy for BMT was 74% with a sensitivity of 46% and specificity of 88%. This study demonstrates that for SMKIs, BMT can be predicted accurately based upon the inhibition of these 19 kinases.
The highly dissimilar sequence motifs of the 19 kinases offered insight into structural modifications that may mitigate this toxicity by reducing the inhibition to the 19 model kinases and the binding pocket sequence motifs they represent while maintaining the desired potency. Although the analysis results suggest that these kinases play a role in BMT, it is possible that for some of the SMKIs that are bone marrow toxic, toxicity may arise in a kinase-independent manner. For example, the toxicity could be potentiated by a metabolite or a certain chemical scaffold rather than from abrogation of cellular function because of kinase inhibition. This phenomenon may help explain the greater specificity than sensitivity of the model. Nevertheless, these results demonstrated a general pattern: SMKIs that potently inhibit one or more of these kinases is more likely to cause BMT in vivo than SMKIs that do not.
The 19 representative kinases were identified by developing and applying a new feature selection algorithm. The algorithm seeks to find kinases that fulfill two criteria. First, the kinase is highly correlated with or predictive of BMT. Second, the binding pocket sequences are dissimilar among the selected kinases. This strategy resulted in the selection of 19 kinases, dissimilar from one another in terms of ATP-binding pocket sequences, but highly correlated with and collectively predictive of the BMT end point. Other kinases may also be significantly correlated with BMT within each of the clusters, but because it is not as highly correlated as the representative kinase, was not included in the final mathematical model (Supplementary table S2) . These criteria were selected to provide actionable information to medicinal chemists during the lead optimization process. Specifically, if a test compound is predicted to be BMT positive by the model and inhibits 
FIG. 4.
Molecular structures of the two p38 SMKIs. The structures (a) compound 1 and (b) compound 2 used in our retrospective analysis. Both compound 1 and compound 2 share a common amino-pyrazole core and inhibit P38a. However, compound 1 was identified to be bone marrow toxic, whereas compound 2 was not bone marrow toxic.
MODELING BMT 271 several of the 19 model kinases, a medicinal chemist can compare the binding pocket sequences of the inhibited kinases with the targeted kinase to highlight sequence differences that can be leveraged in compound structural design. Thus, the aim of this feature selection algorithm was to provide medicinal chemists with a guide during the early drug development phase of lead optimization to improve compound design away from safety concerns while maintaining potency.
A specific example of how this model can be used is demonstrated with docking models for two structurally similar P38a inhibitors: compound 1 and compound 2 (Fig. 5) . Compound 1, a BMT-positive compound, inhibited three kinases that correlate with BMT: P38a, PDGFRB, and LCK. Compound 2 was BMT negative and inhibited P38a but not PDGFRB or LCK. The docking model of compound 2 in P38a highlights the hydrogen bonding interactions with the backbone atoms of Met109 and Thr106 in the hinge region of the kinase in the ATP-binding pocket, and the hydrophobic interaction between the O-ethyl morpholino group and Leu108 (Fig. 5a ). Although parts of the morpholino group are solvent exposed, compound 2 fit ideally within the binding pocket, without steric hindrance. The key interactions with Leu108 were well within the range for ideal hydrophobic packing with the morpholino group of the ligand. On examination of the docking mode of compound 2 within the binding pocket of LCK, it is evident that there was a steric hindrance of the morpholino group (Fig. 5c ) with Tyr318 and hence a predictably dramatic decrease in binding affinity of compound 2 with LCK. The docking model for compound 1 reveals that this molecule should interact well with both P38a and LCK (Figs. 5b and d) because the size of the pyridine group is smaller and more rigid compared with the morpholino group of compound 2. This prediction was confirmed by similar inhibition of P38a and LCK by compound 1. This example demonstrates how this model can be used for hypothesis generation to avoid inhibiting kinases that correlate with BMT (e.g., LCK and PDGFRB) by incorporating structural modifications while maintaining potency for the desired target.
A review of the literature revealed that a large proportion (9/ 19) of the kinases in the model have a function in hematopoietic cells (Table 1 ) that when inhibited theoretically could cause hematopoietic dysfunction or toxicity. MET and its ligand hepatocyte growth factor, for example, play a role in hematopoietic proliferation, adhesion, and survival (Ikehara, 1996; Lai et al., 2006; Weimar et al., 1998) , whereas LCK is an integral component in T-cell signaling (Tewari et al., 2006) . Other kinases with known hematopoietic functions are CSNK1E, PKN1, TGFBR1, PDGFRB, STK10, PIM2, and P38a; however, as demonstrated by Figure 3 and the example given above, inhibition of P38a alone does not appear sufficient to cause BMT. Two of the kinases, AURKC and NEK7, have centrosomal functions during mitosis (Kim et al., 2007; Sasai et al., 2004; Yissachar et al., 2006; O'Regan and Fry, 2009 ) that theoretically could affect hematopoietic proliferation and/or differentiation if inhibited by an SMKI; however, a direct link to hematopoietic function for either was not observed in the literature. The functions for the majority of the remaining kinases (CAMK2A, CLK1, DMPK, EPHB1, CDK17, MYLK2, PAK7, and MNK2) are poorly characterized; thus, additional studies describing their role in the hematopoietic system are warranted. As the model is reductive in nature, other kinases highly correlated with BMT yet were not selected by the model exist (Supplementary table S2) .
Although great care was taken to maximize the model's robustness by selecting a set of SMKIs that were structurally diverse and representative of the overall SMKI library at Roche (PCA plot shown in Supplementary fig. S3 ), a potential limitation was the use of a kinase panel consisting of only 277 kinases. Although this represents a majority of the kinome, there is a possibility that a kinase that plays a key role in BMT is not included in the panel and would not be represented here. However, given that the feature selection method was designed to identify highly dissimilar kinases and that this incorporates all residues within the ATP-binding pocket, the 19 representative kinases have good and broad coverage of the kinome.
One caveat to interpreting the model is that clusters were identified using sequence information prior to choosing cluster representatives. Thus, the kinases selected were those most correlated with BMT within a given cluster but not across the entire dataset. This constraint may make model interpretation difficult, as individual kinases may not appear to be highly correlated with BMT based on its kinase inhibition profile. To this end, we stress the multivariate nature of the model, as well as the use of clustering as a heuristic to guide feature selection, which may not necessarily represent a true reflection of human kinase evolution. Additionally, this study identified kinases that correlate with but may not be causative of BMT. To explore the causal link between each kinase and BMT requires further experimental validation of the mechanistic relevance of the kinases reported here. Nevertheless, we argue that the criteria of this feature selection method present a balance worth having because they provide actionable information to medicinal chemists for hypothesis generation of structural modifications that may avoid a set of kinases while maintaining potency.
The mathematical model approach described provides a rapid accurate method to screen compounds in silico during lead optimization in the early phase of drug development to predict the possibility of BMT prior to the initiation of in vivo preclinical safety testing. Moreover, by comparing the sequences in the binding pocket of the target kinase to that of the 19 representative kinases, this model provides a guide toward structural modifications of SMKIs to avoid BMT.
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